阿帕替尼联合替吉奥治疗TACE术后的原发性肝癌的临床研究

目的：有研究结果显示阿帕替尼联合肝动脉化疗栓塞（TACE）可增加原发性肝癌患者临床疗效，替吉奥联合TACE较单独使用TACE也可延长原发性肝癌患者生存期；本文探讨阿帕替尼联合替吉奥治疗TACE术后的晚期原发性肝癌的临床疗效及安全性。方法：研究2015年6月-2018年4月期间在武汉大学人民医院接受治疗的45例TACE术后晚期肝癌患者的临床资料，根据患者接受治疗方案不同分为2组：阿帕替尼联合替吉奥组（观察组，n=20）和单用替吉奥（对照组，n=25）。观察2组患者的临床疗效，同时评价2组的不良反应。结果：观察组患者的客观缓解率和疾病控制率均高于对照组，但差异无显著性（P>0.05）；观察组的中位无进展生存期是10.7个月，而对照组的中位无进展生存期是9.7月，2组无进展生存期的差异有统计学意义（P<0.05）；观察组中高血压、蛋白尿的发生率明显高于对照组，差异有显著性（P<0.05）。结论：TACE术后晚期原发性肝癌患者口服阿帕替尼联合替吉奥是一种安全、有效的治疗方法，值得临床推广。

The clinical research of apatinib combined with tegafur in the treatment of primary liver cancer after transcatheter arterial chemoembolization

OBJECTIVE The results have shown that Apatinib combined with transcatheter arterial chemoembolization (TACE) can increase the clinical efficacy in patients with primary liver cancer, and the survival of patients with primary hepatocellular carcinoma can also be prolonged by Tegafur combined with TACE compared with TACE alone. the efficacy and safety of apatinib combined with tegafur in the treatment of advanced primary hepatocellular carcinoma after TACE were evaluated.METHODS Clinical data of 45 patients with advanced liver cancer after TACE who received treatment in Renmin Hospital of Wuhan University from June 2015 to April 2018.Patients were divided into two groups according to different treatment regimens:apatinib plus tegafur group (observation group, n=20) and tegafur alone group (control group, n=25).The clinical efficacy of the two groups of patientswereobserved and the adverse reactions of the two groups were also evaluated. RESULTS The objective response rate and disease control rate of the observation group were higher than those of the control group, but the difference had no statistical significance (P>0.05); the median progression-free survival time of the observation group was 10.7 months, while the median progression-free survival time of the control group was 9.7 months, and the difference in the progression-free survival time between the two groups was statistically significancant (P<0.05); the incidence rate of hypertension and proteinuria of the observation group was significantly higher than that of the control group, and the difference was statistically significancant (P<0.05).CONCLUSION Oral Apatinib combined with Tegafur is a safe and effective treatment for patients with advanced primary liver cancer after TACE, which is worthy of clinical promotion.